drugset / Trial / NCT01558271
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 in participants with type 2 diabetes mellitus who are not taking oral antidiabetic medication.
Timeline
- Start
- 2012-03
- Primary completion
- 2013-10
- Completion
- 2014-05
Publications
- Iwamoto N, Matsui A, Kazama H, Oura T. Subgroup Analysis Stratified by Baseline Pancreatic beta-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes. Diabetes Ther. 2018 Feb;9(1):383-394. doi: 10.1007/s13300-017-0346-4. Epub 2017 Dec 20.
- Suzuki S, Oura T, Takeuchi M, Boye KS. Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies. Health Qual Life Outcomes. 2017 Jun 12;15(1):123. doi: 10.1186/s12955-017-0696-7.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dulaglutide | Peptide | 0.75 mg | Subcutaneous |
| Comparator | Liraglutide | Peptide | 0.9 mg | Subcutaneous |